Context Therapeutics doses first patient in Phase 1 trial of CT-95

Context Therapeutics (CNTX) announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95, a mesothelin x CD3 T cell engaging bispecific antibody designed to target mesothelin-expressing cancers. The Company anticipates sharing initial data for the CT-95 Phase 1 trial in mid-2026. This milestone marks Context’s second active clinical trial, following the dosing of the first patient in the CTIM-76 trial earlier this year. CTIM-76 is a Claudin 6 x CD3 TCE bispecific antibody currently being evaluated in CLDN6-positive tumors, including ovarian, endometrial, and testicular cancers.